Kodiak Sciences Stock Surges After Eye Disease Drug Matches Eylea
Kodiak Sciences' stock rose 180% to $90.69 after its eye disease drugs, Zenkuda and tabirafusp alfa tedromer, met primary endpoints in a Phase 3 trial, showing non-inferior vision gains compared to Regeneron's Eylea. The company plans to seek FDA approval for Zenkuda in Q4 2026. Both drugs demonstrated favorable safety profiles and significant efficacy in treating wet age-related macular degeneration.
How this was made
The 30-second read
Why it matters
The data positions Kodiak as a credible competitor to aflibercept‑based therapies, likely accelerating its FDA filing timeline and attracting investor interest.
Market read
First‑report of pivotal trial results creates immediate trading opportunity and may reshape the wet‑AMD market landscape.
What to watch
Potential competition from upcoming biosimilars and the need for reimbursement negotiations.
Background
Kodiak Sciences announced that its two eye‑disease candidates met primary endpoints in a Phase 3 trial, prompting a massive share price jump.
Market effects
Strengthens the wet‑AMD therapeutic segment and may pressure competitors like Roche (VABY) and biosimilar players.
Positive for US biotech sector, especially companies with late‑stage ophthalmology pipelines.
Highlights growing interest in IL‑6 inhibition approaches worldwide.
Counterpoint
If FDA raises concerns about long‑term safety or pricing, the rally could reverse.
Key entities
- companyKodiak Sciences
Biotech firm developing Zenkuda and tabirafusp for ocular diseases.
- companyRegeneron
Maker of Eylea, the comparator in the trial.
